Boston Scientific Corp. (NYSE:BSX) lauded a new guidance released by the research arm of the U.K.’s National Health Service, the country’s publicly funded health care system.
The National Institute for Health & Clinical Excellence issued a final guidance for bronchial thermoplasty as an option for patients with severe asthma that isn’t controllable with drugs, a boon for Boston Scientific’s Alair.